Skip to main content

Advertisement

Log in

New perspectives on assessment of suicide risk

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Concerns have arisen during recent years over a possible link between suicide and medications used to treat several medical conditions, including depression, asthma, epilepsy, and smoking. The concern over the safety of these medications was sparked by data from postmarketing and retrospective analyses of clinical trials. However, clinical trials were not initially designed to measure suicidality, and this methodologic limitation weakens the ability to make causal conclusions. Postmarketing results also have methodologic limitations (such as the absence of control groups) that limit the ability to make causal conclusions. Postmarketing results are also misleading because each of the medical conditions involved is highly comorbid with depression. The risk of not treating these conditions with an active and effective medication may clearly outweigh the possible slight elevation of the risk of suicidal thoughts and behaviors.

The decision to take a medication should be made in consultation with a physician and based upon considerations of the risks and benefits of the medication. Physicians and the public need accurate information on the suicide risks associated with medications to make informed treatment decisions. The most effective way to ascertain the true risk (or lack of risk) associated with a medication is to systematically and prospectively assess suicidal thoughts and behaviors in randomized, placebo-controlled clinical trials. If a medication is scientifically determined to increase the risk for suicidal thoughts and behaviors, then the risk needs to be accurately translated and communicated to physicians and patients. Physicians prescribing these medications will need to closely monitor and assess their patients for changes in mood and suicide risk throughout treatment and must be able to recognize when a patient needs specialized mental health care. Mental status changes can be appropriately monitored and managed. Some medical conditions, such as asthma and epilepsy, and some treatment goals, such as smoking cessation, have inherent increased risks for depression—and by extension, suicide—that necessitate accurate, ongoing assessment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control: Web-based Injury Statistics Query and Reporting System (WISQARS). Available at http://www.cdc.gov/injury/wisqars/index.html. Accessed June 2009.

  2. Moscicki EK: Epidemiology of completed and attempted suicide: toward a framework for prevention. Clin Neurosci Res 2001, 1:310–323.

    Article  Google Scholar 

  3. Harris EC, Barraclough B: Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997, 170:205–228.

    Article  PubMed  CAS  Google Scholar 

  4. Posner K, Oquendo MA, Gould M, et al.: Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007, 164:1035–1043.

    Article  PubMed  Google Scholar 

  5. US Food and Drug Administration: Suicidality in children and adolescents being treated with antidepressant medications (10/15/2004). Available at http://www.fda.gov/Drugs/Drug-Safety/PublicHealthAdvisories/ucm161679.htm. Accessed May 27, 2009.

  6. US Food and Drug Administration: Antidepressant Use in Children, Adolescents, and Adults. Available at http://www.fda.gov/cder/drug/antidepressants/default.htm. Accessed May 27, 2009.

  7. Gibbons RD, Brown CH, Hur K, et al.: Relationship between antidepressants and suicide attempts: an analysis of the veterans health administration data sets. Am J Psychiatry 2007, 164:1044–1049.

    Article  PubMed  Google Scholar 

  8. Olfson M, Shaffer D, Marcus SC: Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003, 60:978–982.

    Article  PubMed  Google Scholar 

  9. Gibbons RD, Brown CH, Hur K, et al.: Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007, 164:1356–1363.

    Article  PubMed  Google Scholar 

  10. Galil N: Depression and asthma in children. Curr Opin Pediatr 2000, 12:331–335.

    Article  PubMed  CAS  Google Scholar 

  11. Katon W, Lozano P, Russo J, et al.: The prevalence of DSMIV anxiety and depressive disorders in youth with asthma compared with controls. J Adolesc Health 2007, 41:455–463.

    Article  PubMed  Google Scholar 

  12. Goodwin RD, Eaton WW: Asthma, suicidal ideation, and suicide attempts: findings from the Baltimore Epidemiologic Catchment Area Follow-Up. Am J Public Health 2005, 95:717–722.

    Article  PubMed  Google Scholar 

  13. US Food and Drug Administration: Postmarket Drug Safety Information for Patients and Providers. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety-InformationforPatientsandProviders/default.htm. Accessed May 27, 2009.

  14. Kanner AM: Depression in epilepsy: a complex relation with unexpected consequences. Curr OpinNeurol 2008, 21:190–194.

    Google Scholar 

  15. Christensen J, Vestergaard M, Mortensen PB, et al.: Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 2007, 6:693–698.

    Article  PubMed  Google Scholar 

  16. US Food and Drug Administration: Information for healthcare professionals: suicidal behavior and ideation and antiepileptic drugs (1/31/2008, updated 12/16/2008). Available at http://www.fda.gov/cder/drug/InfoSheets/HCP/antiepileptics200812.htm. Accessed May 26, 2009.

  17. Centers for Disease Control and Prevention: Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995–1999. MMWR 2002, 51:300–303. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5114a2.htm. Accessed May 27, 2009.

    Google Scholar 

  18. American Psychiatric Association: Practice guidelines—assessment and treatment of patients with suicidal behaviors. Available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic_14.aspx. Accessed May 27, 2009.

  19. Gliatto MF, Rai AK: Evaluation and treatment of patients with suicidal ideation. Am Fam Physician 1999, 59:1500–1506.

    PubMed  CAS  Google Scholar 

  20. Jacobs D, Brewer M: APA practice guideline provides recommendations for assessing and treating patients with suicidal behaviors. Psychiatr Ann 2004, 34:373–380.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to James E. Gangwisch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gangwisch, J.E., Jacobson, C.M. New perspectives on assessment of suicide risk. Curr Treat Options Neurol 11, 371–376 (2009). https://doi.org/10.1007/s11940-009-0041-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-009-0041-5

Keywords

Navigation